The Latest Breaking News from Eli Lilly

GLP-1 users are suing over vision loss: What does the evidence really show?

Dozens of patients have taken legal action against drug manufacturers, filing personal injury lawsuits that allege they were not adequately warned about the risk of a rare type of sudden vision loss, ABC News reported.

The Economic Times · Sep 24

Hundreds of Lawsuits Allege Ozempic and Other GLP-1 Drugs Caused Sudden Vision Loss, but Absolute Risk Appears Low

Hundreds of lawsuits claim Ozempic and other GLP-1 drugs caused sudden vision loss. What the evidence shows, who faces the most risk, and symptoms to know.

Medical Daily · Sep 24

700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient

Eli Lilly says 700,000 US seniors started GLP-1 treatment through Medicare's Bridge scheme, with taxpayers covering about $195 per patient each month.

International Business Times UK · Sep 24

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is…

The Economic Times · Sep 21

5 Buy-and-Hold Stocks Built to Weather a Volatile Market

Ahead of Q4 2026, analysts favor Western Digital, NVIDIA, Vertiv, Eli Lilly, and JPMorgan Chase as steady, best-in-class stocks offering growth with less volatility for buy-and-hold investors.

MarketBeat · Sep 16

3 Healthcare Stocks for 3 Stages of Life

Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.

MarketBeat · Sep 15

Two Drugmakers Paid More Than a Quarter Million American Prescribers as Weight Loss Drug Sales Climbed

An analysis of federal payment data found Eli Lilly and Novo Nordisk paid over 250,000 US prescribers as GLP-1 weight loss drug sales grew.

Medical Daily · Sep 10

Can a New Weight Loss Treatment Escape the Legal and Regulatory Thicket?

It’s Eli Lilly vs. RFK Jr. in a battle over the rules around retatrutide.

Reason · Sep 10

A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today

Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.

Barchart · Aug 31

‘Who knows what they’re taking?’: people risk the gray market for the newest weight-loss drug

Retatrutide, not yet approved by the FDA, is the latest wonder drug to shed pounds despite warnings from doctors

The Guardian - US · Aug 31